STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

|  |  |  |  |
| --- | --- | --- | --- |
|  | Item No | Recommendation | Page No |
| **Title and abstract** | 1 | (*a*) Indicate the study’s design with a commonly used term in the title or the abstract | (a): 28 dni, EMA Naslov ne vsebuje, da gre za opazovalno študijo. |
| (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | (b): Povzetek vsebuje cilj, načrt raziskave, metode, rezultate in zaključke.  *Str. 1* |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Obširena predstavitev ozadja.  *Str. 2 – 3, poglavje 2* |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses |  |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | Primeren opis.  *Str. 3, poglavje 3.2* |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Opisana časovna raporeditev študije (v katerem tednu je posameznik izvajal določene naloge). Potek raziskave je povzet samo meseci in leti (brez točnih datumov).  Opredeljena lokacija.  Opis zbiranja podatkov.  *Str. 3-4, poglavja 4.1, 4.2, 4.3, 4.4* |
| Participants | 6 | (*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | (a): Kriteriji za preiskovance so našteti v protokolu študije. To je zapisano v članku.  *Str. 3, poglavje 4.1* |
| (*b*)For matched studies, give matching criteria and number of exposed and unexposed | (b) Ne omenjajo enakih raziskav. |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Definiran je izid študije, spremenljivke so podrobno definirane v protokolu študije (je napisano v članku), zunanji dejavniki v študiji niso bili privzeti (omenjeno v omejitvah študije), definirano visoko in nizko tveganje (effect modifiers), diagnostična merila so podorbno opisana v protokolu študije, navedena pa v študiji.  *Str. 3-4, poglavje 4.3, 4.4, 4.5*  *Str. 9, zadnji odstavek* |
| Data sources/ measurement | 8\* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Navedeni viri podatkov za spremenljivke (npr, samomorilno razmušljanje – EMA, spanje in aktivnost – nosljiva naprava, …). Navedeno, da je zbiranje opisano v protokolu študije.  Opisana delitev v dve skupini (nizko in visoko rizična skupina).  *Str. 3-4, poglavje 4.2, 4.3, slika Str. 1, povzetek* |
| Bias | 9 | Describe any efforts to address potential sources of bias | Določene pristranskosti so omenjene, določene delno – nekatere so omenjene v protokolu, nekatere v omejitvah študije.  Omenjena je pristranskost convenience sampling, uporabljena metoda EMA, izpad udeležencev iz študije, težavo samoporočanja, nezajemanje nekaterih zunanjih spremenljivk, …  *Str. 3, poglavje 4.1, 4.3*  *Str. 9* |
| Study size | 10 | Explain how the study size was arrived at | Opisano v protokolu študije. |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Opisn namen in način delitve v dve skupini.  *Str. 1, povzetek,*  *Str. 3, poglavje 4.1* |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | (a): Navedeno, da so metode opisane v protokolu študije.  *Str. 4, poglavje 4.5* |
| (*b*) Describe any methods used to examine subgroups and interactions | (b): Opisane metode za primerjavo razlik med skupinama v protokolu študije. |
| (*c*) Explain how missing data were addressed | (c): Niso imeli mankajočih podatkov, napisan izpad sodelujočih iz študije.  *Str. 3, poglavje 4.1* |
| (*d*) If applicable, explain how loss to follow-up was addressed |  |
| (*e*) Describe any sensitivity analyses | (e): Omenjno, kako se težko posplošuje rezultate.  *Str. 9* |
| Results | | |  |
| Participants | 13\* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | (a): Opredeljeno skupno število sodelujočih, izpad sodelujočih, ni opredeljeno kdaj so izstopili iz študije, je opredeljeno zakaj so izstopili. Vsi sodelujejo v vseh fazah raziskave.  *Str. 3, poglavje 4.1* |
| (b) Give reasons for non-participation at each stage | (b) Ni potrebno. |
| (c) Consider use of a flow diagram | (c) Ne vsebuje. |
| Descriptive data | 14\* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | (a): Predstavljeno v tabeli.  *Str. 6-7, tabela 1* |
| (b) Indicate number of participants with missing data for each variable of interest | (b): Ni mankajočih podatkov. |
| (c) Summarise follow-up time (eg, average and total amount) | (c): Ni follow upa. |
| Outcome data | 15\* | Report numbers of outcome events or summary measures over time | Opredeljeno končno število opazovanih posameznikov, ni vmesnih rezultatov. Podani končni rezultati statistične analize.  *Str. 8, tabela 2,  Str. 4, poglavje 5* |

|  |  |  |  |
| --- | --- | --- | --- |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | (a): Podani končni rezultati stat. analize s pripadajočimi SD in p-vrednostmi.  *Str. 8, tabela 2*  *Str. 4, poglavje 5* |
| (*b*) Report category boundaries when continuous variables were categorized |  |
| (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |  |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses |  |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Poglobljen opis rezultatov, dodani rezultati, p-vrednosti v oklepajih. Interpretacija rezultatov.  *Str. 4-8, poglavje 5* |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Opisane v diskusiji in že pred tem omenjene v protokolu študije.  *Str. 9* |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Podana interpretacija rezultatov, opis drugih študij in izpostavljeno kaj je drugače. Ni podanih številskih rezultatov drugih študij, samo povzetki.  *Str. 7-10, poglavja 6, 6.1 Str. 2-3, poglavje 2* |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results |  |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |  |

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.